Microbot Medical Inc. announced on January 6, 2025, that it has entered into definitive agreements for a registered direct offering. The offering involves the purchase and sale of 4,000,002 shares of the company’s common stock at a price of $1.75 per share.
In a concurrent private placement, Microbot Medical will also issue unregistered short-term series G preferred investment options. These options allow for the purchase of up to 8,000,002 shares of common stock at an exercise price of $1.75 per share, exercisable for two years.
The gross proceeds to the company from this registered direct offering and concurrent private placement are expected to be approximately $7 million. Microbot Medical intends to use the net proceeds for the continued development, commercialization, and regulatory activities for its LIBERTY Robotic System, as well as for general corporate purposes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.